[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].

Nobuki Hayakawa, Atsushi Suzuki

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

Original languageEnglish
Pages (from-to)1383-1390
Number of pages8
JournalClinical calcium
Volume22
Issue number9
Publication statusPublished - 01-01-2012

Fingerprint

Osteoporotic Fractures
Hypoglycemic Agents
Osteoporosis
Diabetes Mellitus
Incretins
Medicine
Bone and Bones
Thiazolidinediones
Dipeptidyl-Peptidase IV Inhibitors
Mesenchymal Stromal Cells
Type 2 Diabetes Mellitus
Meta-Analysis
Clinical Trials
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{15de73ed94db4547a0e730537ef8de9d,
title = "[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].",
abstract = "Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.",
author = "Nobuki Hayakawa and Atsushi Suzuki",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "22",
pages = "1383--1390",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "9",

}

[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture]. / Hayakawa, Nobuki; Suzuki, Atsushi.

In: Clinical calcium, Vol. 22, No. 9, 01.01.2012, p. 1383-1390.

Research output: Contribution to journalReview article

TY - JOUR

T1 - [Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

AB - Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

UR - http://www.scopus.com/inward/record.url?scp=84875103339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875103339&partnerID=8YFLogxK

M3 - Review article

VL - 22

SP - 1383

EP - 1390

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 9

ER -